Listing of Claims:

Claims 1-20 (Canceled)

21. (Previously Presented) An oral fixed combination administration form for an active compound, which is a pyridin-2-ylmethylsulfinyl-1H-benzimidazole or a pharmaceutically acceptable salt thereof, which comprises the active compound in a capsule in two different administration forms, which release the active compound at two different points of time, wherein one administration form comprises the active compound together with a tablet disintegrant and bears a coating film which is customary per se for sustained - release compositions, and wherein the other administration form comprises the active compound and bears and enteric coating film.

22. (Previously Presented) An oral fixed combination administration form as claimed in claim 21, wherein the pyridin-2-ylmethylsulfinyl-1H-benzimidazole is pantoprazole.

23. (Previously Presented) An oral fixed combination administration form as claimed in claim 22, wherein each administration form is in pellet form.

24. (Previously Presented) An oral fixed combination administration form as claimed in claim 22, wherein each administration form is in tablet form.

25. (Previously Presented) An oral fixed combination administration form as claimed in claim 22, wherein the tablet disintegrant is Crospovidone.

26. (Previously Presented) An oral fixed combination administrative form as claimed in claim 22, wherein the coating film which is customary per se for sustained-release compositions is a copolymer of acrylic and methacrylic acid esters having quaternary ammonium structures.

27. (Previously Presented) An oral fixed combination administration form as claimed in claim 22, which is suitable for once daily administration of pantoprazole or a pharmaceutically acceptable salt thereof instead of a twice daily administration.

28. (Previously Presented) A method of treating an amenable disorder of the stomach which comprises administering to a subject in need of such therapy an effective amount of an oral fixed combination administration form as claimed in claim 21.

29. (Previously Presented) A method of treating an amenable disorder of the stomach which comprises administering to a subject in need of such therapy an effective amount of an oral fixed combination administration form as claimed in claim 22.

30. (Previously Presented) A method of treating an amenable disorder of the stomach which comprises administering to a subject in need of such therapy an effective amount of an oral fixed combination administration form as claimed in claim 23.

31. (Previously Presented) A method of treating an amenable disorder of the stomach which comprises administering to a subject in need of such therapy an effective amount of an oral fixed combination administration form as claimed in claim 24.

32. (Previously Presented) A method of treating an amenable disorder of the stomach which comprises administering to a subject in need of such therapy an effective amount of an oral fixed combination administration form as claimed in claim 25.

33. (Previously Presented) A method of treating an amenable disorder of the stomach which comprises administering to a subject in need of such therapy an effective amount of an oral fixed combination administration form as claimed in claim 26.

34. (Previously Presented) A method of treating an amenable disorder of the stomach which comprises administering to a subject in need of such therapy an effective amount of an oral fixed combination administration form as claimed in claim 27.

35. (New) An oral fixed combination administration form according to claim 21 wherein the administration form which comprises the active compound together with a tablet disintegrant releases said active compound only after gastric passage.

36. (New) An oral fixed combination administration form according to claim 21 wherein the administration form which comprises the active compound together with a tablet disintegrant releases said active compound, once release thereof has commenced, within a short space of time, so that a rapidly rising and high active compound blood level is achieved.

37. (New) An oral fixed combination administration form according to claim 21 wherein the administration form which comprises the active compound together with a tablet disintegrant releases said active compound after gastric passage spontaneously and completely.

38. (New) An oral fixed combination administration form according to claim 21 wherein the administration form is that of a pharmaceutically acceptable salt selected from the group consisting of a calcium salt, a magnesium salt, a potassium salt and a sodium salt.

39. (New) An oral fixed combination administration form according to claim 21 wherein the tablet disintegrant is a member selected from the group consisting of a cellulose derivative, a starch, sodium carboxymethylstarch, bentonite, sodium alginate, pectin and crosslinked polyvinylpyrrolidone.

40. (New) An oral fixed combination administration form according to claim 21 wherein the tablet disintegrant is sodium carboxymethylcellulose or potato starch.

41. (New) An oral fixed combination administration form according to claim 21 wherein each administration form has a core which contains a further auxiliary, filler, binder, stabilizer, or any combination thereof.

42. (New) An oral fixed combination administration form according to claim 41 wherein the stabilizer is a pharmacologically tolerable alkali metal, alkaline earth metal or earth metal salt of a weak acid or a pharmacologically tolerable hydroxide or oxide of an alkaline earth metal or of an earth metal.

43. (New) An oral fixed combination administration form according to claim 21 wherein the coating film which is customary per se for sustained-release compositions is a water-insoluble and physiologically tolerable plastic membrane having low swelling power in water and in which small soluble particles are imbedded.